Worsening of psoriasis with rituximab therapy

Clinical and Experimental Rheumatology

Volumn 28, Issue 6, 2010, Pages 926-

  Olivieri, I ^a,b   D'Angelo, S ^a   Leccese, P ^a   Vertone, D ^b   Olivieri, A ^b  

^a MADONNA DELLE GRAZIE HOSPITAL   (Italy)

^b SAN CARLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; INFORMED CONSENT; LARGE CELL LYMPHOMA; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; SPINE RADIOGRAPHY; TREATMENT DURATION; TREATMENT PLANNING; CHEMICALLY INDUCED DISORDER; NOTE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PREDNISONE; PSORIASIS; VINCRISTINE;

EID: 79952711513     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. Markatseli TE, Kaltsonoudis ES, Voulgari PV, Zioga A, Drosos AA: Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol 2009; 27: 996-8.
2. Singh F, Weinberg JM: Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphoma. Cutis 2005; 76: 186-8.
3. Coiffier B, Lepage E, Briere J et al:. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
4. Emery P, Fleishmann R, Filipowicz-Sosnowska A et al:. FOR THE DANCER STUDY GROUP: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase lib randomized, double-blind, placebo controlled, dose ranging trial. Arthritis Rheum 2006; 54: 1390-400.
5. Cohen SB, Emery P, Greenwald MW et al:, FOR THE REFLEX TRIAL GROUP: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: a result of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twentyfour weeks: Arthritis Rheum 2006; 54: 2793-806.
6. Mielke F, Schneider-Obermeyer J, Dorner T: Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 2008; 67: 1056-7.
7. Dass S, Vital EM, Emery P: Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007; 56: 2715-8.
8. Scarpa R, Ayala F, Caporaso N, Olivieri I: Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 2006; 33: 210-2.
9. Cohen JD: Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis 2008; 67: 1647-8.